Q-linea AB (publ) announced that the company has finished the clinical trials for the drug Meropenem-Vaborbactam with strong results and is therefore able to claim IVDR compliance and add the drug to the existing BC-GN panel. The company expects commercial availability in Europe during Second Quarter 2024. Meropenem-Vaborbactam is a combination drug of a Carbapenem and a beta-lactamase inhibitor with enhanced activity against gram-negative organisms, particularly Enterobacterales with class A and C carbapenemases.